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Trine Mølbæk Jensen1, Signe Kjeldgaard Jensen1, Lisbeth Marianne Thøstesen3, Poul-Erik Kofoed3,
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Abstract
Background: The Bacillus Calmette-Guérin vaccine (BCG) against tuberculosis is administered intradermally, and
vaccination is often followed by a scar at the injection site. Among BCG-vaccinated individuals, having a scar has
been associated with lower mortality. We aimed to examine the impact of vaccination technique for scarring in a
high income setting, by assessing the associations between the post injection reaction, the wheal size, and the
probability of developing a scar, and scar size.
Methods: This study was nested within a clinical multicenter study randomizing 4262 infants to either BCG vaccination (BCG
1331 SSI) or no intervention. In this substudy, including 492 vaccinated infants, the immediate post BCG vaccination reaction
was registered as either wheal (a raised, blanched papule at the injection site), bulge (a palpable element at the injection site),
or no reaction. The presence or absence of a BCG scar and the size the scar was measured at 13 months of age.
Results: Of 492 infants included, 87% had a wheal after vaccination, 11% had a bulge, and 2% had no reaction. The mean
wheal size was 3.8 mm (95% confidence interval 3.7–3.9). Overall, 95% (442/466, 26 lost to follow-up) of BCG-vaccinated
infants had a scar at 13 months of age. In infants with a wheal, the probability of developing a scar was 96%, declining to
87% in the case of a bulge, and to 56% in the case of no reaction (p for same probability = 0.03). Wheal size was positively
correlated with the probability of getting a scar and scar size.
Conclusion: Scarring after BCG vaccination has been associated with lower infant mortality. In a high-income setting, we
found that correct injection technique is highly important for the development of a BCG scar and that registration of the
category of BCG skin reaction (as wheal, bulge, or no reaction) may be used to identify infants at risk of scar failure. Finally,
the wheal size was positively associated with both the probability of getting a scar and scar size.
Trial registration: The study was registered at www.ClinicalTrials.gov with trial registration number NCT01694108.
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Background
Tuberculosis (TB) still represents a great threat to global
health. It is estimated that approximately one third of the
world’s population is currently infected with latent TB,
and 2 million people die of TB each year [1]. Despite on-
going efforts to develop new and more effective TB vac-
cines [2], BCG remains the only licensed vaccine against
TB. BCG has been administered to billions of infants and
is one of the most commonly used vaccines worldwide [3].
Following a correct administered intradermal BCG vaccin-
ation, a transient post injection wheal is usually observed;
often, but not always, followed by a pustule and a flat scar at
the injection site [4]. The presence or absence of a scar is
often used as an indicator of BCG vaccination in a clinical
context as well as in health surveys to assess vaccine coverage
[5]. However, not all children develop a scar. Several factors,
such as correct vaccination technique [3, 6], dose of vaccine
[7, 8], BCG strain [9–11], sex of the child [6, 12], age at vac-
cination [12–14], and prior tuberculin sensitivity [15] have
been described to impact scarring. Furthermore, immune
characteristics in the infant prior to vaccination may be
important for scar development [10]. Importantly, among
BCG-vaccinated individuals, having a scar has been associ-
ated with reduced mortality [16–18] and in a recent study
conducted in West Africa, mortality for scar-positive in-
fants was found to be half that of scar-negative infants [10].
Between 2012 and 2015, we conducted The Danish
Calmette Study [19], a randomized multicenter trial aiming
to study the impact of neonatal BCG on morbidity
outcomes. Despite the widespread use of BCG through
decades there is no standard or point of reference for the
measurement of post vaccination reaction or scar assess-
ment. In the present substudy, we aimed to examine the
importance of vaccination technique for scarring using the
BCG (1331 SSI) in a setting with no routine BCG vaccin-
ation and a low prevalence of TB [20] and HIV [21],
providing reference material for measurements of post
vaccination reaction and scar size and frequency in a high
income setting. We assessed the association between the
post injection reaction, the wheal size and the probability of
developing a scar and scar size. We hypothesized that
having a wheal would be associated with a higher scar fre-
quency, and that an increase in wheal size would increase
the probability of getting a scar and the size of the scar.
Methods
Setting
This substudy was nested within the Danish Calmette study,
described in detail elsewhere [19]. In brief, infants were ran-
domized within 7 days of birth with a 1:1 allocation to either
BCG vaccination or no intervention. The inclusion criteria
were gestational age ≥ 32 weeks and a birth weight ≥ 1000 g.
Exclusion criteria were maternal intake of immune modu-
lating medicine during pregnancy or signs of severe illness
or major malformation in the newborn. A total of 4262 in-
fants were enrolled, and children who were allocated to
BCG vaccination received the BCG strain SSI 1331. The
vaccination procedure was conducted according to the
manufacturer’s instructions [22], using the standard-of-care
intradermal Mantoux injection technique [23]. The vaccine
was stored at 2–8 degrees °C at the maternity wards prior
to use. A sterile 1 mL syringe with a short (25–27 G) needle
was used for the injection of 0.05 mL of the vaccine suspen-
sion intradermally in the deltoid region of the left arm.
The present study
The present substudy was conducted at two of the three
randomization sites: Copenhagen University Hospital,
Hvidovre and Copenhagen University Hospital, Rigshospi-
talet. From February 7th to November 28th 2013, infants
randomized to BCG by two members of our study staff (A
and B) at Copenhagen University Hospital, Hvidovre, were
included into this substudy. From May 29th to October
31st 2013 infants randomized to BCG by one member of
our study staff (C) at Copenhagen University Hospital,
Rigshospitalet, were included. We aimed to include a
minimum of 500 infants (Fig. 1).
Measurements of the BCG vaccination skin reaction and scar
Immediately after the administration of the BCG vaccine, the
size of the BCG vaccination skin reaction was assessed.
Firstly, the skin reaction was categorized as either A) “wheal”,
if a raised, blanched papule was visible at the injection site
(Fig. 2a), B) “bulge”, if no visible wheal emerged but there
was a palpable bulge, or C) no reaction [6]. Secondly, in the
case of a wheal, the longest diameter or length (as not all
wheals were round in shape) of the wheal was measured
(mm) once with a transparent ruler (Tuberculin PPD RT 23
SSI, Copenhagen, Denmark) (Fig. 2a). The assessors of the
BCG vaccination skin reaction were midwifes (A and C), and
a medical student (B) trained in the procedure of BCG
vaccination and measurement of BCG vaccination skin reac-
tion in connection with the present study. None of the asses-
sors were experienced prior to commencement of the study.
The presence of a scar (yes/no) and the scar size (mm)
was assessed within the entire Danish Calmette Study at the
age of 13 months (Fig. 2b). The longest diameter or length
(as not all scars were round in shape) of the scar was
measured twice, followed by a repeated measurement of the
diameter/length perpendicular to this. The mean of these
four measurements was used as the estimate of scar size.
Statistical methods
The association between BCG vaccination skin reaction
(wheal, bulge, no reaction) and scar (yes/no) as well as the
association between wheal size (mm) and scar (yes/no)
were analyzed as prevalence data assessed in Poisson re-
gression models with robust variance estimates [24], with
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the scar variables as outcomes and the BCG vaccination
skin reaction category and wheal size, respectively, as
covariates. Among children with a scar, the association be-
tween the size of the wheal (mm) and the size of the scar
(mm) was examined using linear regression analysis, with
the scar size as outcome and wheal size as covariate. One
scar size estimate of 27.5 mm was considered an outlier
and was excluded from the analysis.
On the basis of previous findings that the ability of
BCG to induce scars may be differentiated by sex [10]
both overall and sex-stratified estimates were calculated.
Sex of the child, vaccinator (A, B, C), and study
months (months 1–12, since season of birth is thought
to affect the immune system) were assessed as potential
confounders by including them as covariates in the stat-
istical models. Since birth weight was positively associ-
ated with wheal size (but not with category of BCG skin
reaction, scar size, or scar frequency), birth weight was
also included as a covariate in the statistical analyses
concerning wheal size.
Analysis of predefined potential effect modifiers: sex of
the child, vaccinator (A, B, C), age at vaccination (0–1 day
Fig. 1 Inclusion into the study on the association between BCG vaccination skin reaction (categorized as wheal, bulge, or no reaction) and the
subsequent development of a scar
Fig. 2 The association between BCG vaccination skin reaction and the subsequent development of a scar. a Measurement of the size of a BCG
vaccination wheal at birth. b Subsequent round and flat scar on the infant’s upper left arm at 13 months of age
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vs. 2–7 days), season, study months (1–12), scar examiner
(1–9), and maternal BCG (yes/no) were conducted. A 5%-
significance level was used. All analyses were performed
using STATA 13.1 (StataCorp LP, College Station, Texas).
Ethical considerations
This substudy, as part of the protocol of the main trial, was
approved by the Committees on Biomedical Research Ethics
(J.no. H-3-2010-087), the Danish Data Protection Board
(J.no. 2009–41-4141), and the Danish Medicines Agency
(J.no.2612–4356.EudraCT 2010–021979-85. Protocol 2009–
323). The study was registered at www.ClinicalTrials.gov
with trial registration number NCT01694108. The trial was
supervised by the Good Clinical Practice Units of the
Capital Region, Denmark and monitored by an independent
Data Safety Monitoring board. This study was performed in
accordance with the Declaration of Helsinki. Infants were
included after both oral and written information had been
provided and a signed consent form from both parents had
been obtained.
Results
A total of 514 BCG-vaccinated infants were eligible for
inclusion into this substudy; 22 were excluded due to lack
of registration that enabled pairing of outcome and child in
the case of twins, or erroneously assigned study id num-
bers on the sheet where the BCG skin reaction was regis-
tered (Fig. 1). Of the remaining 492 infants, 87% (427/492)
had a wheal after vaccination, 11% (56/492) had a bulge,
and 2% (9/492) had no reaction. Overall, 95% (442/466, 26
lost to follow-up) of BCG-vaccinated infants developed a
scar, in equal number of boys and girls (Fig. 1).
Baseline characteristics for infants in this study are shown
in Table 1. Baseline characteristics in the present study
were similar to those of infants in The Danish Calmette
Study, except for ‘age at vaccination’; 15% of infants in this
study were vaccinated <1 day of age vs. 48% in the Danish
Calmette study, p < 0.001 (Additional file 1: Table S1A).
This was due to the fact that Copenhagen University
Hospital, Hvidovre generally included children 1–2 days
later than the two other recruitment sites.
BCG vaccination wheal size, scar size, and scar rate
In infants with a wheal, the mean wheal size was 3.8 mm,
95% confidence interval (CI) (3.7–3.9); 3.9 mm for boys
and 3.8 mm for girls (p = 0.09 for same wheal size in boys
and girls). The overall mean scar size was 4.6 mm, 95% CI
(4.5–4.8), 4.7 mm for boys and 4.5 mm for girls (p = 0.06
for same scar size in boys and girls) (Table 2). The three
vaccinators did not produce same wheal size (range 3.5–
4.3, p < 0.001), or scar frequency (range 93–100%,
p < 0.001) (Table 2). Baseline characteristics for infants vac-
cinated by the three vaccinators differed for level of mater-
nal education, p = 0.002 (Additional file 2: Table S2B).
The association between category of BCG vaccination
skin reaction (wheal/bulge/no reaction) and scar
The probability of developing a scar following a post
vaccination wheal was 96%. The probability of develop-
ing a scar was 87% following a post vaccination bulge
and 56% following no visible or palpable post vaccin-
ation reaction (Fig. 3). The incidence rate ratio (IRR) of
getting a scar preceded by a bulge was 0.90, 95% CI
(0.80–0.98) (wheal as reference). Furthermore, the IRR
of getting a scar preceded by no reaction was 0.57, 95%
CI (0.31–0.99) (wheal as reference). The difference
between the three types of BCG skin reactions and the
subsequent probability of developing a scar was signifi-
cant (p = 0.03). Adjustment for sex of the child, vaccin-
ator, and study months (1–12) did not change the result:
the aIRR of getting a scar preceded by a bulge was 0.90;
the aIRR of getting a scar preceded by no reaction was
0.58, (p < 0.001).
The association between BCG vaccination skin reac-
tion and BCG scar was different for the three vaccina-
tors (p for same association = 0.008): Vaccinator A had
an IRR for bulge of 0.87, 95% CI (0.77–0.99) and an IRR
of 0.52, 95% CI (0.26–1.03) for no reaction. Vaccinator B
had an IRR for bulge of 1.08, 95% CI (1.01–1.20), and
Table 1 Baseline characteristics for children randomized to BCG
in the study on the association between BCG vaccination skin
reaction and the development of a scar
BCG skin reaction & scar
study
n = 492
Sex (male)a 257 (52%)
Prematurity (GA < 37) 10 (2%)
Caesarean section 108 (22%)
Birth weight in grams
(mean ± SD)
3501 ± 504
Age at time of randomization
<1 day
75 (15%)
Maternal BCG 92 (19%) [2]
At least one parent of non-Danish
ethnicity
98 (20%)[0]
Maternal smoking during pregnancy 49 (10%)[0]
Level of maternal education [1]
Basic schooling and non-theoretical
education
96 (20%)
Theoretical education incl. BA level 212 (43%)
Master level or more 183 (37%)
Siblings 192 (39%)
Atopic predispositionb 336 (68%)
a n number (Frequency) [not available] unless otherwise stated
b Atopic predisposition defined as at least one first degree relative with atopic
disease. Atopic disease is defined as physician-diagnosed atopic eczema,
asthma, and allergic rhino conjunctivitis or food allergy
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IRR = 1.08, 95% CI (1.03–1.15) for no reaction. Vaccin-
ator C could not be evaluated, as there were no children
with no reaction.
The association between BCG vaccination skin reac-
tion and BCG scar was similar across age at vaccination,
sex, season, study months, maternal BCG, and scar
examiner (data not shown).
The association between size of BCG vaccination wheal
and the development of a scar
In infants with a BCG vaccination wheal, we found an
association between wheal size and the prevalence of
having a scar, the birth weight adjusted aIRR being 1.03,
95% CI (1.01–1.06), p = 0.005. This corresponds to a 3%
increase in the probability of getting a scar, when wheal
size increased by 1 mm. Adjusting the analysis for sex,
vaccinator, and study months did not change the result:
IRR 1.03, 95% CI (1.01–1.05), p < 0.001.
Again, vaccinator was a significant effect modifier, the IRR
in the association between wheal size and the prevalence of
having a scar for vaccinator A was 1.04, 95% CI (1.01–1.07)
and for B it was 0.99, 95% CI (0.96–1.02). Vaccinator C pro-
duced 100% scars, p value for interaction = 0.02.
The association between BCG vaccination wheal size
and chance of a BCG scar was similar across age at vac-
cination, sex, season, study months, maternal BCG, and
scar examiner (data not shown).
BCG vaccination wheal size and scar size, among infants
with a BCG scar
Assessing the association between the wheal and scar
size by linear regression analyses, the birth weight
adjusted regression coefficient was 0.10 mm/mm, 95%
CI 0.01–0.19, p = 0.02. Hence, scar size increased with
0.1 mm when wheal size increased with 1 mm (Fig. 4).
After adjustment for sex, vaccinator, and study month,
the regression coefficient was 0.11 mm/mm, 95% CI
(0.03–0.21), p = 0.01.
The association between BCG vaccination wheal size
and scar size was similar across vaccinators, age at vac-
cination, sex, season, study months, maternal BCG, and
scar examiner (data not shown).
Discussion
In a high-income setting, we found that the categories of
post-vaccination skin reaction (wheal, bulge, or no reac-
tion) predicted substantially different scar frequencies.
Furthermore, an increase in wheal size raised both the
probability of getting a scar and increase in scar size.
Previous reports of wheal size after the injection of
0.05 ml BCG intradermally vary from 2.0 mm (IQR 0.0–3.0)
in newborns vaccinated within 48 h after birth [25] to
4.9 mm (mean) at 6 months of age [7] and 6.3 mm in school
children [8]. Age has been shown to be positively associated
Table 2 An overview of the outcomes of the study assessing BCG vaccination skin reaction and subsequent scaring - stratified by
sex and vaccinator
Wheal Bulge No reaction Wheal size (mm) Scar No scar Scar size (mm)
n (%) n (%) n (%) mean (95% CI) n n (%) n (%) mean (95% CI) n
Total 427 (87) 56 (11) 9 (2) 3.8 (3.7–3.9) 395 442 (95) 24 (5) 4.6 (4.5–4.8) 442
Boy 227 (88) 29 (11) 1a (1) 3.9 (3.7–3.9) 205 232 (95) 12 (5) 4.7 (4.5–4.8) 232
Girl 200 (85) 27 (12) 8 (3) 3.8 (3.6–3.9) 190 210 (95) 12 (5) 4.5 (4.3–4.7) 210
Vaccinator
A 307 (84) 49 (14) 8 (2) 3.8 (3.7–3.9) 280 326 (94) 20 (5) 4.7 (4.5–4.9) 326
B 59 (92) 4 (6) 1 (2) 3.5 (3.3–3.8) 55 53 (93) 4 (6) 4.1 (3.8–4.5) 53
C 61 (95) 3 (5) 0 (0) 4.3 (4.1–4.4)b 60 63 (100)c 0 (0) 4.8 (4.5–5.1) 63
aThe categories of “wheal”, “bulge”, and “no reaction” were unevenly distributed between sexes, p = 0.04
bThere was a significant difference in wheal size between the three vaccinators, p < 0.001
cThere was a significant difference in scar rate between the three vaccinators, p < 0.001
Wh
ea
l
Bu
lge
No
 re
ac
tio
n
0
50
100
%
Scar
No scar
*
Fig. 3 The association between three categories of BCG vaccination
skin reaction (wheal, bulge, or no reaction) registered immediately
after neonatal BCG vaccination and the probability (%) of developing a
scar at 13 months of age. The IRR of getting a scar preceded by a
‘bulge’ (with ´wheal´ as reference), was 0.90; the IRR of getting a scar
preceded by ´ no reaction ´ was 0.57, *indicates p = 0.03
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with wheal size [7], and our mean wheal size (3.8 mm) may
reflect the relatively early age of vaccination in our study
(median age in days 1, 10–90 percentiles (1–2)) . However,
infants in our study may be slightly older than the South Af-
rican newborns (with a median wheal of 2.0 mm [25]) as in-
fants were vaccinated within 7 days after birth in our study
vs. within 48 h after birth in the study by Geldenheys et al.
[25]. Differences in wheal size may also be due to genetic
differences between the study populations or differences in
exposure to environmental mycobacterial antigens [26]. Our
overall scar frequency (95%) corresponds to scar frequencies
found in studies from urban sub Saharan Africa (91–
94%)4,6,9 and the UK (100%) [26].
The development of a scar after BCG vaccination has
been used as one of the indicators for successful vaccin-
ation and in estimating vaccine coverage [12]. Since
BCG is administered throughout the world as the only
licensed preventive vaccine against TB, post-vaccination
scaring as a BCG signature remains important. Although
the efficacy of BCG in the protection against TB has
been highly debated, a recent study from Greenland
found BCG vaccination effective in reducing both
mycobacterial infection and TB disease in children and
adolescents [27]. The presence of a scar has not been
found to correlate with the protection against TB [28,
29]; this may however reflect the varying efficacy of
BCG against TB [30]. In a setting of routine BCG vac-
cination, studies from West Africa have shown that
BCG vaccination may be associated with lower mortality
[31, 32]. Among BCG-vaccinated individuals, having a
scar was associated with further reduced mortality
[16–18]. For instance, in a recent study from rural
Guinea-Bissau, mortality for scar-positive infants was
found to be half that of scar-negative infants [10].
This may be related to underlying differences in the
immune systems of children who developed or did
not develop a BCG scar. However, the association
between having a scar and lower mortality was
comparable in populations with low (52%) [10] and
high(>90%) [16, 18]scar frequencies. Hence, it seems
more likely that scar is a marker of a correctly ad-
ministered BCG vaccine. These findings suggest that
it may be important to monitor the development of a
BCG scar as a marker of a well-functioning vaccin-
ation program. Future clinical trials may further
examine if revaccinating infants with scar failure may
improve survival in low-income countries.
Thus, confirming the findings from low-income settings,
our results show that vaccination technique, i.e. correct
intradermal administration of neonatal BCG is highly im-
portant for scarring. In our high-income setting, using the
BCG SSI 1331, getting a wheal converts into a scar
frequency of 93–100%, depending on vaccinator. Infants
who developed a bulge, but no wheal, presumably got the
vaccine subcutaneously [6]. This resulted in a lower scar
frequency than administration leaving a wheal, which was
visibly intradermal. These findings corroborate previous
studies showing that subcutaneous administration of BCG
induced less recognizable/fewer scars than intradermal
administration [7] and that intradermal administration
formed a higher scar rate (94%) compared to subcutane-
ous administration (82%) [6]; scar rates which were com-
parable to ours of 96% following intradermal BCG vs. 87%
following subcutaneous BCG.
Fig. 4 Violin plot of the association between size of the wheal and size of the scar measured at 13 months in infants vaccinated with BCG at
birth. The open circle in the center of the plots depicts the median scar size at a given wheal size, the box depict the interquartile range, and the
spikes depict the upper and lower values. The light gray areas reflect the density of the data
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A marked reduction in scar frequency (56%) was seen
when no reaction was formed post vaccination. This cat-
egory, most likely covered both deep (intra cutaneous/
intra muscular) administration of vaccine and no or little
vaccine given (perforation of the skin or reflux of the
vaccine through the injection canal). In a recent study
from rural Guinea-Bissau, a surprisingly low overall scar
frequency of 52% was found [10], comparable to our
findings after ‘no reaction’. The authors suggest several
explanatory factors, among them poor vaccination tech-
nique, due to less experienced and lack of specialized
nurses in the rural areas. It was also suggested that BCG
strain may play a role, since most of the children got the
Russian BCG strain, which has been associated with a
lower scar frequency in more studies [10, 33].
We also found that BCG vaccine wheal was directly
associated with the size of the scar (Fig. 4). This again
corroborates previous studies [7, 8], however, worth noting,
the effect on scar size in the present study (regression coef-
ficient = 0.10 mm/mm) indicates that determinants other
than wheal size are important for scar size. Furthermore, as
seen for scar frequency, wheal size and scar rate varied
among vaccinators. These differences should, however, be
seen in the light of the different inclusion periods into this
study. Vaccinator C, who presented bigger wheals and scar
rate, began enrollment close to 4 months after vaccinators
A and B, and had therefore acquired more experience.
When comparing baseline characteristics for infants vacci-
nated by the three vaccinators, only level of maternal
education differed; suggesting that differences in baseline
characteristics are not likely to explain the differences in
wheal size and scar rate observed between vaccinators.
Despite the widespread use of BCG there is no gold
standard for the measurement of post vaccination wheal
or scar. This study reduces this knowledge gap by pre-
senting reference material from a prospective study on
healthy infants assessed within a standardized setup in a
high income country with a low burden of TB and pro-
vides a unique possibility for further follow-up through
the national registers.
A strength of this study is the standardized study setup;
BCG vaccination was done by members of our study staff
specifically trained in the vaccination procedure and in
measuring outcomes according to the study protocol. A
limitation lies within the different inclusion periods at the
two sites, and experience level at inclusion start may have
differed. Although the study included 492 infants, only 9
infants had no reaction post vaccination, and this is a
limitation to the study. Mothers included in the Danish
Calmette Study and hence in this substudy, were of higher
education and parents had a higher prevalence of atopic
predisposition than the background population [34] which
may limit the generalizability to the overall Danish popula-
tion. Of interest, but out of scope for this study, would
have been to assess tuberculin skin test (TST) reaction,
since studies have shown vaccination technique, dose of
vaccine injected, and type of vaccine to determine both size
and frequency of TST reaction as well as BCG scar [6, 18].
Conclusion
In conclusion, we demonstrated that the skin reaction at
the injection site is highly important for the probability of
developing a scar after neonatal BCG vaccination (1331
SSI) in a high-income setting. Compared with presenting a
wheal at the site of injection after BCG vaccination, having
no reaction was associated with a reduced probability of
developing a scar by >40%. Hence, training in correct injec-
tion technique may greatly improve the probability of
getting a BCG scar. Registration of the category of BCG
skin reaction immediately after vaccination may be used to
identify infants at risk of scar failure. Focus on improving
BCG vaccination technique may improve BCG scar
frequency, with potential benefits for both vaccine coverage
surveillance and child mortality in low-income countries.
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28. Sterne JA, Fine PEM, Pönnighaus JM, Sibanda F, Munthali M, Glynn JR. Does
bacille Calmette-Guerin scar size have implications for protection against
tuberculosis or leprosy? Tuber. Lung Dis. 1996;77:117–23.
29. Fine PEM, Sterne JAC, Pönnighaus JM, Rees RJW. Delayed-type
hypersensitivity, mycobacterial vaccines and protective immunity. Lancet.
1994;344:1245–9.
30. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, et al.
Tuberculosis. Nat Rev Dis Prim. 2016;2:16076.
31. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, et al. Randomized
trial of BCG vaccination at birth to low-birth-weight children: beneficial
nonspecific effects in the neonatal period? J Infect Dis. 2011;204:245–52.
32. Biering-Sørensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, et al.
Small Randomized Trial Among Low–birth-weight Children Receiving
Bacillus Calmette-Guéerin Vaccination at First Health Center Contact. Pediatr
Infect Dis J. 2012;31:306–8.
33. Frankel H, Byberg S, Bjerregaard-Andersen M, Martins CL, Aaby P, Benn CS,
et al. Different effects of BCG strains - A natural experiment evaluating the
impact of the Danish and the Russian BCG strains on morbidity and scar
formation in Guinea-Bissau. Vaccine. 2016;34:4586–93.
34. Stensballe LG, Sørup S, Aaby P, Benn CS, Greisen G, Jeppesen DL, et al. BCG
vaccination at birth and early childhood hospitalisation: a randomised
clinical multicentre trial. Arch Dis Child. 2016;archdischild-2016-310760.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Birk et al. BMC Infectious Diseases  (2017) 17:540 Page 8 of 8
